Key Highlights

  • Loss per share was USD 3.47 against an estimate of a USD 0.45 loss.
  • Net loss attributable to common stockholders was USD 23.93 million.
  • Total operating expenses were USD 25.06 million, against USD 17.02 million.
  • Cash and marketable securities were USD 402.5 million at September 30.

Electra Therapeutics (NASDAQ:ETRA) reported a third quarter 2026 loss per share of USD 3.47, against an estimate of a USD 0.45 loss. Net loss attributable to common stockholders was USD 23.93 million. The report is the company's quarterly filing following its initial public offering in September 2026.

The loss from operations was USD 25.06 million, compared with USD 17.02 million in the third quarter of 2025.

Operating Expenses

Research and development expenses were USD 17.27 million, compared with USD 14.90 million. General and administrative expenses were USD 7.79 million, compared with USD 1.81 million, and general and administrative expenses to a related party were zero, compared with USD 308 thousand. Total operating expenses were USD 25.06 million, compared with USD 17.02 million.

The filing reports Research and Development expense for Options of USD 1.54 million, compared with USD 114 thousand, and research and development expense for profits interest units of USD 25 thousand, compared with USD 30 thousand.

Nine-Month Results and Other Income

For the nine months ended September 30, 2026, total operating expenses were USD 75.29 million, compared with USD 42.39 million, with the loss from operations equal to that amount in both periods. Research and development expenses for the nine months were USD 58.9 million, compared with USD 33.7 million, and general and administrative expenses were USD 16.4 million, compared with USD 8.7 million.

Interest income increased to USD 1.1 million from USD 0.2 million for the quarter, and to USD 2.5 million from USD 0.6 million for the nine months. Interest expense decreased to zero from USD 1.3 million for the quarter, and to zero from USD 1.6 million for the nine months.

Initial Public Offering and Cash

The company completed its IPO in September 2026, receiving proceeds of USD 325.5 million, net of Underwriting discounts and commissions, but before deducting offering costs payable by the company of USD 5.5 million. As of September 30, 2026, the company had cash, cash equivalents and marketable securities of USD 402.5 million.

The filing states that the 2026 Employee Stock Purchase Plan, approved by the board in August 2026, became effective upon execution of the underwriting agreement for the IPO on September 17, 2026. It also states that, immediately before the closing of the IPO, the Series A redeemable convertible Preferred Shares received in the LLC distribution were converted into shares of common stock, and describes awards with an exercise price of USD 4.96 per share that vest ratably on a monthly basis over four years, subject to the achievement of specified operational milestones approved by the board.

Electra Therapeutics Q3 2026 Earnings: Key Takeaways

Electra Therapeutics reported a third quarter 2026 loss per share of USD 3.47 and total operating expenses of USD 25.06 million. The company received IPO proceeds of USD 325.5 million, net of underwriting discounts and commissions, and held USD 402.5 million of cash and marketable securities.